Table 4.
Parkinson’s disease participant demographics
| Demographic and clinical variables | Newly diagnosed, non-medicated PD (n = 10) | Treated PD (n = 10) | P value |
|---|---|---|---|
| Age, mean (SD) | 62.90 (6.89) | 65.70 (9.03) | 0.45 |
| Sex, n (%) | |||
| Men | 5 (50%) | 6 (60%) | 1.00 |
| Women | 5 (50%) | 4 (40%) | |
| Race & ethnicity | |||
| White, n (%) | 10 (100%) | 10 (100%) | 1.00 |
| Not Hispanic or Latino, n (%) | 10 (100%) | 10 (100%) | 1.00 |
| Disease characteristics | |||
| Age of disease onset, mean (SD) | 61.30 (6.01) | 59.50 (9.96) | 0.63 |
| Disease duration, mean (SD) | 1.95 (1.30) | 6.20 (4.51) | 0.01* |
| H&Y, mean (SD) | 2 (0) | 2 (0) | 1.00 |
| UPDRS motor, mean (SD) | 12 (5.09) | 14.9 (5.62) | 0.24 |
| Levodopa equivalent dose | |||
| Median (IQR) | NA | 393.75 (333.00) | – |
| Range | NA | 100–1387.5 | – |
| Bristol Stool Score, mean (SD) | 3.20 (1.54) | 2.20 (1.75) | 0.19 |
IQR interquartile range, H&Y Hoehn and Yahr staging scale, NA not applicable, SD standard deviation, UPDRS Unified Parkinson’s Disease Rating Scale.
*Significance: P value <0.05. n = 20 PD participants.
Two-tailed Student’s t test or chi-square test were used for analyses.